Comparative study: Exploring the Advantages of Tb-161 over Lu-177 in Targeted Radionuclide Therapy and the impact of Antagonist vs Agonist

C. Ntihabose; M. Handula; S. Beekman; A. Piet; L. van Dalen; J. Zink; D. Stuurman; C. de Ridder; G. Tamborino; M. Konijnenberg; T. Brabander; J. Nonnekens; Y. Seimbille; E. de Blois

doi:10.1007/s00259-024-06838-z

Comparative study: Exploring the Advantages of Tb-161 over Lu-177 in Targeted Radionuclide Therapy and the impact of Antagonist vs Agonist

C. Ntihabose, M. Handula, S. Beekman, A. Piet, L. van Dalen, J. Zink, D. Stuurman, C. de Ridder, G. Tamborino, M. Konijnenberg, T. Brabander, J. Nonnekens, Y. Seimbille, E. de Blois

Research output: Contribution to journal › Meeting Abstract › Academic

1 Downloads (Pure)

Original language	English
Article number	EP-0995
Pages (from-to)	S830-S830
Number of pages	1
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	51
DOIs	https://doi.org/10.1007/s00259-024-06838-z
Publication status	Published - Sept 2024
Event	Annual Congress of the European-Association-of-Nuclear-Medicine (EANM) - Hamburg, Germany Duration: 19 Oct 2024 → 23 Oct 2024

Access to Document

10.1007/s00259-024-06838-z

Comparative studyFinal published version, 1.59 MBLicence: Article 25fa Dutch Copyright Act

Cite this

Ntihabose, C., Handula, M., Beekman, S., Piet, A., van Dalen, L., Zink, J., Stuurman, D., de Ridder, C., Tamborino, G., Konijnenberg, M., Brabander, T., Nonnekens, J., Seimbille, Y., & de Blois, E. (2024). Comparative study: Exploring the Advantages of Tb-161 over Lu-177 in Targeted Radionuclide Therapy and the impact of Antagonist vs Agonist. European Journal of Nuclear Medicine and Molecular Imaging, 51, S830-S830. Article EP-0995. https://doi.org/10.1007/s00259-024-06838-z

@article{45e3c3ddcac3412da6e56dbbfad0d67c,

title = "Comparative study: Exploring the Advantages of Tb-161 over Lu-177 in Targeted Radionuclide Therapy and the impact of Antagonist vs Agonist",

author = "C. Ntihabose and M. Handula and S. Beekman and A. Piet and {van Dalen}, L. and J. Zink and D. Stuurman and {de Ridder}, C. and G. Tamborino and M. Konijnenberg and T. Brabander and J. Nonnekens and Y. Seimbille and {de Blois}, E.",

year = "2024",

month = sep,

doi = "10.1007/s00259-024-06838-z",

language = "English",

volume = "51",

pages = "S830--S830",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer-Verlag",

note = "Annual Congress of the European-Association-of-Nuclear-Medicine (EANM) ; Conference date: 19-10-2024 Through 23-10-2024",

}

Ntihabose, C, Handula, M, Beekman, S, Piet, A, van Dalen, L, Zink, J, Stuurman, D , de Ridder, C , Tamborino, G, Konijnenberg, M, Brabander, T , Nonnekens, J , Seimbille, Y & de Blois, E 2024, 'Comparative study: Exploring the Advantages of Tb-161 over Lu-177 in Targeted Radionuclide Therapy and the impact of Antagonist vs Agonist', European Journal of Nuclear Medicine and Molecular Imaging, vol. 51, EP-0995, pp. S830-S830. https://doi.org/10.1007/s00259-024-06838-z

TY - JOUR

T1 - Comparative study

T2 - Annual Congress of the European-Association-of-Nuclear-Medicine (EANM)

AU - Ntihabose, C.

AU - Handula, M.

AU - Beekman, S.

AU - Piet, A.

AU - van Dalen, L.

AU - Zink, J.

AU - Stuurman, D.

AU - de Ridder, C.

AU - Tamborino, G.

AU - Konijnenberg, M.

AU - Brabander, T.

AU - Nonnekens, J.

AU - Seimbille, Y.

AU - de Blois, E.

PY - 2024/9

Y1 - 2024/9

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=eur_pure&SrcAuth=WosAPI&KeyUT=WOS:001332779404008&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1007/s00259-024-06838-z

DO - 10.1007/s00259-024-06838-z

M3 - Meeting Abstract

SN - 1619-7070

VL - 51

SP - S830-S830

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

M1 - EP-0995

Y2 - 19 October 2024 through 23 October 2024

ER -

Comparative study: Exploring the Advantages of Tb-161 over Lu-177 in Targeted Radionuclide Therapy and the impact of Antagonist vs Agonist

Access to Document

Other files and links

Cite this